General Manager and VP of Business Development, Built Robotics
| Role | Organisation | Sources |
|---|---|---|
| General Manager and VP of Business Development | Built Robotics | RenewEconomy, Mirage News, ARENA (Tue 13 Oct 2026), ARENA (Wed 31 Jul 2024) |
| Chairman (former) | Hatchtech | OneVentures portfolio, GBS Ventures |
| Founder | OneVentures | OneVentures team page |
| Partner and Managing Director (former) · Founder | OneVentures | Startup Daily (Fri 29 Aug 2025), Startup Daily (Tue 26 Aug 2025), Startup Daily (Wed 17 Jan 2024), Brandon Capital portfolio, Brandon BioCatalyst portfolio, OneVentures portfolio (Sun 2 Aug 2020), OneVentures portfolio (Sat 4 May 2019), einpresswire.com, labonline.com.au (Tue 10 Feb 2015), SmartCompany, labonline.com.au (Tue 2 Aug 2011), OneVentures team page |
| Director (former) | Vaxxas | Startup Daily (Fri 29 Aug 2025), SmartCompany, Startup Daily (Tue 26 Aug 2025), Business News Australia, sprim.com, labonline.com.au |
Stories naming Dr Paul Kelly. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
The renewable energy agency is backing two companies with grants totalling $32.3 million to manufacture robots that build solar farms, with production hubs planned for Melbourne and Brisbane.
Weekly roundup detailing five Australian raises: Vaxxas' Series D plus debt facility amid executive changes, Skutopia's growth round, Send Payments' backing and CEO change, Apate.ai's seed, and Coursebox's seed.
Also Startup Daily·SmartCompany·Australian FinTech·Dealroom·Startup Daily
Australian biotech Vaxxas secured a Series D plus a debt facility while overhauling leadership: a new chair, founding CEO shifting to an advisory role, and CFO made redundant amid job cuts.
Also Business News Australia·SmartCompany·Cut Through Venture·Startup Daily·Startup Daily·SmartCompany·Startup Daily
Vaxxas announced a roughly A$90m financing — Series D equity led by SPRIM Global Investments plus debt — to advance its needle-free vaccine patch, alongside leadership changes including a new chair.
The renewable energy agency commits grant funding to two solar projects: forecasting software at PV Lighthouse and robot automation of solar farm construction at Built Robotics.
Manufacturing sector roundup: Whyalla steelworks resumes production, Maggie Beer Holdings' chief executive to depart, ReNu Energy secures hydrogen funding, Defence names grant recipients, Orthocell gains Canadian approval, and AEA appoints its advisory board.
Prota Therapeutics, a Melbourne biotech, has secured $32 million in equity and debt ahead of a Phase 3 trial of its peanut allergy therapy, with Singapore's SPRIM Global Investments leading the round.
Also SmartCompany·SmartCompany·SmartCompany·Business News Australia·Forbes Australia
Perth fintech PictureWealth has bought out licence holders Futuro Financial Services and Insight Investment Services from majority owner Highfield Group, with existing leaders staying on as chairman Dennis Bashford plans succession.
Vaxxas completed a US$23 million (A$34 million) financing led by OneVentures and UniQuest to advance its needle-free vaccine clinical programs, including a COVID-19 candidate, with board members, management and individual investors also participating.
Also OneVentures portfolio·Brandon Capital portfolio·@AuManufacturing·SmartCompany·Techboard·@AuManufacturing
OneVentures appoints Jim Scopa and Dan Baker to its healthcare investment team, and recalls its Healthcare Fund III backing Blade Therapeutics and BiVACOR.
Diagnostics company Clinical Genomics closed a $15m Series A led by Sydney VC OneVentures to commercialise its blood test for monitoring bowel cancer recurrence; OneVentures partner Dr Paul Kelly joins its board.
Vaxxas completed a $25 million Series B led by OneVentures, lifting total capital to $40 million, to advance its needle-free Nanopatch vaccine delivery technology toward first clinical studies.
Australian pharmaceutical developer Hatchtech appoints Tim Waugh, a former Roche divisional vice president, as chief executive officer to lead development and commercialisation of its head lice treatment DeOvo and establish a United States presence.
Biotech startup Vaxxas has raised $15 million in venture capital, led by OneVentures with Brandon Capital, MRCF and HealthCare Ventures, to commercialise the Nanopatch needle-free vaccine delivery technology developed at Queensland university institute AIBN.